The Evolving Role of Cytoreductive Surgery in Metastatic Bladder Cancer
For years, the standard approach to metastatic bladder cancer relied heavily on systemic treatments, with surgery often viewed as a tool for symptom management rather than a curative attempt. However, the landscape is shifting. A new era of systemic therapies is reviving the conversation around cytoreductive surgery, offering a potential path toward improved survival and better quality of life for a specific subset of patients.
Beyond Chemotherapy: The Impact of New Systemic Therapies
The traditional “chemotherapy era,” dominated by regimens like gemcitabine-cisplatin, often yielded limited responses for patients with metastatic or regionally advanced bladder cancer. This made the prospect of cytoreductive cystectomy—removing the bladder to reduce the overall tumor burden—less common.
The tide is turning due to the success of the EV-302 trial. The combination of enfortumab vedotin and pembrolizumab has produced deep and durable responses in patients. These “incredible responses” have created a new subset of surgical candidates who may now be eligible for consolidative surgery to further stabilize their disease.
Who Benefits Most? The Science of Patient Selection
Not every patient with metastatic disease is a candidate for surgery. The decision is highly individualized and managed by a multidisciplinary team. Recent data suggests that the number and location of metastases are critical predictors of success.
A retrospective analysis of patients treated between 2004 and 2019 highlighted a significant difference in overall survival (OS) for those undergoing cytoreductive radical cystectomy (CRC) compared to conservative local treatment (CLT):
- CRC Group: Median overall survival of 20.4 months.
- CLT Group: Median overall survival of 12.0 months.
The data indicates that CRC is particularly effective for patients with only distant lymph node (LN) metastases, any organ metastasis, or a single visceral metastasis. However, the benefit is less clear for patients with multiple metastases, where the surgery did not significantly improve overall survival.
Understanding the Procedures: From TURBT to Metastasectomy
Cytoreductive surgery is not a one-size-fits-all approach. Depending on the cancer’s location and stage, surgeons may employ different techniques:
Transurethral Resection of Bladder Tumor (TURBT): Here’s a common procedure used to remove tumors from the bladder. The surgeon inserts instruments through the urethra, meaning no skin incisions are required.
Metastasectomy: In some cases, surgery extends beyond the bladder to remove areas where the cancer has spread. This may involve removing the bladder entirely or making larger incisions—such as a long cut across the middle of the abdomen—to remove tumors from the lining of abdominal organs.
Balancing the Benefits and Risks
While the potential for longer life and increased chemotherapy effectiveness is a major driver, these procedures carry inherent risks. Patients undergoing surgery with incisions may face complications such as:
- Bleeding and wound infections
- Blood clots
- Rare reactions to anesthesia
Even minimally invasive procedures like TURBT have long-term considerations. Because cancer may return, patients often require repeat TURBT surgeries. Over time, this can lead to bladder scarring, which may result in urinary incontinence or a need to urinate more frequently due to a decreased ability to hold urine.
Frequently Asked Questions
What is cytoreductive surgery for bladder cancer?
It is the surgical removal of the main tumor in the bladder and potentially other nearby tissues or metastatic sites to reduce the overall cancer burden in the body.
Can surgery help metastatic bladder cancer patients live longer?
Yes, according to some research, cytoreductive radical cystectomy has been associated with an increase in median overall survival (20.4 months vs 12.0 months in certain study cohorts), particularly for those with single visceral or lymph node metastases.
Is TURBT the same as a cystectomy?
No. TURBT is a procedure to remove tumors through the urethra without external incisions, while a cystectomy involves the removal of the bladder.
Who is the ideal candidate for this surgery?
Typically, patients who have responded well to systemic therapies (such as those in the EV-302 trial) and those with limited metastatic spread are considered the best candidates.
Join the Conversation: Are you or a loved one navigating treatment options for metastatic bladder cancer? Share your experiences in the comments below or subscribe to our newsletter for the latest updates on oncological breakthroughs.
